This study provides novel insights into the USP6NL/EGFR axis that suppresses anticancer therapeutic responses, induces cancer invasiveness, and facilitates reduced sensitivity to TMZ treatment in GBM in an autolysosome-dependent manner. This evidence concerns the gene EGFR and cancer.